DNA barcoding reveals ongoing immunoediting of clonal cancer populations during metastatic progression and in response to immunotherapy [DNA barcodes: CD8 NK depletion 4T1 BC5000]

To investigate immunoediting at the primary tumour, we used DNA barcoding combined with NGS. By stably integrating 4T1 murine cancer cell line with 5000 unique DNA barcodes (1 barcode per cell), we can trace how barcode (and therefore subclonal) diversity changes over time and after treatment with immunotherapy. The data provided are generated by targeted barcode sequencing of the primary tumour and lungs collected from barcoded 4T1 tumour bearing mice treated with ket-cell type depleting antibodies, either anti-CD8 to deplete CD8+ cells, anti-asialo GM1 to deplete NK cells or control anitbodies.